Specialty Pharmacy

A nanoparticle delivery system may help manage autoimmune diseases, such as multiple sclerosis, leaving a temporary black mark on patients.

A 7-year study identified genetic pathways hijacked by cancer stem cells to promote tumor growth.

Device shows promise preventing cancer cells from migrating to other organs in the body.

Top news of the day from across the health care landscape.

Pharma has had little incentive to develop drugs for diseases such as malaria, which killed more than 400,000 people last year.

Stelara is the first biologic approved for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.

Effective clinical programs in specialty pharmacy encourage adherence and lead to superior treatment outcomes.

Shutting off a critical enzyme in lipid synthesis found to stifle tumor growth.

Funding of $24 million will support programs and studies that address HIV-infection and prevention among at-risk groups.

Top news of the day from across the health care landscape.

A potential mechanism for the early detection of gastric cancer may lead to better treatment and prognosis.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.

Drug-carrying synthetic polymer could deliver treatment to lung cancer cells without harming healthy cells.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.

Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.

Top news of the week in cancer research.

The promise of sentinel lymph node biopsies for melanoma highlighted at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.

Immune checkpoint inhibitors could improve malignant melanoma therapy, according to a study presented at the Congress of the European Academy of Dermatology and Venerology.

Whether or not cancer cells remain in a cancer patient while undergoing treatment may effect multiple myeloma survival.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

Adherence programs needed to boost Xeljanz utilization for rheumatoid arthritis.

Top articles of the week on Specialty Pharmacy Times.

DHODH inhibitor caused a reduction in leukemic stem cells and long-term remission in mice.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Researchers create a treatment approach that singles out HIV reservoirs.

Top news of the day from across the health care landscape.